The FDA has granted Israel-based EarlySense Ltd. approval for its EverOn system, a heart and lung monitor that uses a proprietary contact-free sensor to reduce patient discomfort and enable monitoring at home and at hospitals. The system, which is being tested on patients with chronic diseases, is expected to be available next year.

Full Story:
Globes (Israel)

Related Summaries